Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Keros Therapeutics, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. (“Keros” or “the Company”) (NASDAQ: KROS). Investors who purchased Keros securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Keros has violated federal securities laws.
Investigation Details
On December 12, 2024, Keros issued a press release “announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension (‘PAH’), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.” On this news, Keros’s stock price fell $50.22 per share, or 73.15%, to close at $18.43 per share on December 12, 2024. Then, on January 15, 2025, Keros issued a press release “announc[ing] that it has voluntarily halted all dosing in the TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension (‘PAH’), including the 1.5 mg/kg and placebo treatment arms, based on the ongoing safety review due to new observations of pericardial effusion adverse events.” Keros further stated that “[t]he Company has notified investigators and certain regulatory authorities, including the FDA, about this decision, and is in the process of notifying other relevant regulatory authorities.” On this news, Keros’s stock price fell $2.06 per share, or 16.51%, to close at $10.42 per share on January 15, 2025.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Keros securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
KROS — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”